

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Demographic data and prevalence of BAFFR-P21R and BAFFR-H159Y polymorphisms in the patients of the study.

Parameter	Total	Group 1	Group 2	Group 3	Group 4	Group 5	p
No	240	65	85	15	56	19	
Sex (male/female)	165/75	44/21	58/27	9/6	41/15	13/6	
Age (mean ± SD), y	40.6 ± 2.2	35.1 ± 3.4	30.8 ± 2.4	45.1 ± 9.4	52.9 ± 4.4	62.5 ± 6.9	
BAFFR-P21R							
No (%) with genotype							0.119
C/C (wt)	213 (88.8)	57 (87.7)	79 (92.9)	12 (80.0)	51 (91.1)	14 (73.7)	
C/G (heter)	27 (11.2)	8 (12.3)	6 (7.1)	3 (20.0)	5 (8.9)	5 (26.3)	
No (%) with allele							0.141
C	453 (94.4)	122 (93.8)	164 (96.5)	27 (90.0)	107 (95.5)	33 (86.8)	
G	27 (5.6)	8 (6.2)	6 (3.5)	3 (10.0)	5 (4.5)	5 (13.2)	
BAFFR-H159Y							
No (%) with genotype							0.141
C/C (wt)	237 (98.8)	65 (100)	83 (97.6)	14 (93.3)	56 (100)	38 (100)	
C/T (heter)	3 (1.2)	0 (0)	2 (2.4)	1 (6.7)	0 (0)	0 (0)	
No (%) with allele							0.143
C	477 (99.4)	130 (100)	166 (98.8)	29 (96.7)	112 (100)	76 (100)	
T	3 (0.6)	0 (0)	2 (1.2)	1 (3.3)	0 (0)	0 (0)	

Abbreviations: The patients are divided in five (5) Groups as described in Material and Methods. Genotype and allele frequencies were analyzed using Chi-square tests. The statistical significance threshold was set at two-sided $p < 0.05$. The statistical package SPSS v.25 was utilized for the analysis.